OVERVIEW

Creating Impact in the Treatment and Prevention of Recurrent C. Difficile Infection is organized by Society of Infectious Diseases Pharmacists (SIDP) and will be held from Aug 01, 2019 - Oct 28, 2020.

Accreditation:
Pharmacists
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers.

Nurses
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.

Course Description:
C. difficile infection (CDI) recurs in nearly 25% of patients. Ideally, the primary treatment goal should be reduction of recurrence. However, in patients experiencing recurrence, the goal shifts to treating therapy resistance. This is especially important given that the risk of recurrence increases after each unsuccessful treatment. This activity will address gaps identified by prior activity feedback and literature review to address patient education and counseling reminders to reduce the risk of recurrence, patient-specific risk factors for recurrent CDI, recommended and emerging treatments for recurrent CDI, and factors in health-system reduction of rCDI. A special focus on techniques to address recurrence and spread will be reinforced with case studies.

Learning Objectives:
The target audience for this activity includes pharmacists and nurses. At the completion of this activity, the participant will be able to:
• Outline patient risk factors for recurrent C. difficile infections and strategies to reduce recurrence rates.
• Compare and contrast recommended and emerging treatment options for recurrent C. difficile infections.
• Describe techniques for staff and patient education to reduce the recurrence and spread of C. difficile infections.
• Discuss financial and reimbursement issues related to hospital C. difficile infection (CDI) rates and pay for performance measures.